4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Actuate Therapeutics, Inc. Common stock (ACTU) operates in the Biotechnology industry and is headquartered in Fort Worth, United States with about 12 employees. Its market capitalization is roughly $28 million. In the fiscal year ended 2025-12-31, ACTU reported $0M in revenue and ($22M) in net income.
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($22M) | ($25M) | ($25M) | ($20M) |
| Net Income | ($22M) | ($27M) | ($25M) | ($20M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($6M) | ($5M) | ($6M) | ($6M) | ($6M) | — |
| Net Income | ($6M) | ($5M) | ($5M) | ($6M) | ($6M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $14M | $9M | $3M | $20M |
| Total Liabilities | $6M | $9M | $103M | $96M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ACTU viewer.
About TickerBase · Data methodology & sources